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background: Recent reports have documented the feasibility of transcatheter valve implantation within surgical tissue valves that have sustained 
structural degeneration and failed.
Methods: Patients with symptomatic severe stenosis or regurgitation of a surgical aortic tissue valve who were at extreme high-risk for an open 
redo operation (estimated surgical mortality or serious morbidity >50%, inoperable) were enrolled in a prospective multicenter PARTNER II valve-in-
valve registry. Patients were excluded if the surgical valve’s labeled size was <21mm or if the internal diameter of the aortic bioprostheses was too 
large for a 26mm SAPIEN XT balloon-expandable transcatheter heart valve.
results: Thirty-day follow up was available for 96 patients. Mean age was 80.1+9.3 years and 55.2% were male. The STS predicted risk of 
mortality was 9.9+5.1%. General anesthesia was utilized in 92.6%, procedure duration was 129+298 minutes, contrast utilized was 73+74ml, and 
cardiopulmonary bypass was utilized in 1.1%. No patient required acute conversion to open redo aortic valve replacement. The pathology of the 
surgical tissue valve was primarily stenosis in 57%, regurgitation in 18%, and both in 25% patients. The reported surgical valve size was 21mm in 
30%, 23mm in 44%, 25mm in 20%, and 27mm in 9%. The SAPIEN XT implant was 23mm in 76.3% and 26mm valve in 23.7%. A single valve was 
implanted in 95.8%, no valve in 3.1% and 2 valves in 1%. The valve position was acceptable in 98.9%, and too aortic in 1.1%. At 30 days all-cause 
mortality was 8.3% (8/96 patients). Adjudicated outcomes at 30 days and echocardiographic core lab analysis will be available.
conclusions: Transcatheter valve replacement is a reproducible and safe alternative for the management of high-risk patients with deterioration of 
aortic surgical tissue valves. Enrollment and follow up continues in the PARTNER II aortic valve-in-valve registry.
